Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Unfortunately, the antibody (ID:146251) is no longer available.
Below is a list of antibodies to the same protein target. You may also try your search again using the search box at the top of the page.
Please contact us if you have any questions.
leucine-rich repeat kinase 2
Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway. The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes. Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner. Regulates neuronal process morphology in the intact central nervous system (CNS). Phosphorylates PRDX3. May also have GTPase activity. May play a role in the phosphorylation of proteins central to Parkinson disease.
LRRK2 expression in normal and pathologic human brain and in human cell lines. Miklossy J, Arai T, Guo JP, Klegeris A, Yu S, McGeer EG, McGeer PL. Journal of neuropathology and experimental neurology. 2006 65:953-63.
Leucine-rich repeat kinase 2 associates with lipid rafts. Hatano T, Kubo S, Imai S, Maeda M, Ishikawa K, Mizuno Y, Hattori N. Human molecular genetics. 2007 16:678-90.
A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Melrose HL, Kent CB, Taylor JP, Dachsel JC, Hinkle KM, Lincoln SJ, Mok SS, Culvenor JG, Masters CL, Tyndall GM, Bass DI, Ahmed Z, Andorfer CA, Ross OA, Wszolek ZK, Delldonne A, Dickson DW, Farrer MJ. Neuroscience. 2007 147:1047-58. (IHC, WB)
LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Alegre-Abarrategui J, Ansorge O, Esiri M, Wade-Martins R. Neuropathology and applied neurobiology. 2008 34:272-83.
LRRK2 and neurodegeneration. Santpere G, Ferrer I. Acta neuropathologica. 2009 117:227-46.
LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. Saha S, Guillily MD, Ferree A, Lanceta J, Chan D, Ghosh J, Hsu CH, Segal L, Raghavan K, Matsumoto K, Hisamoto N, Kuwahara T, Iwatsubo T, Moore L, Goldstein L, Cookson M, Wolozin B. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2009 29:9210-8.
LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Alegre-Abarrategui J, Christian H, Lufino MM, Mutihac R, Venda LL, Ansorge O, Wade-Martins R. Human molecular genetics. 2009 18:4022-34.
Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Venderova K, Kabbach G, Abdel-Messih E, Zhang Y, Parks RJ, Imai Y, Gehrke S, Ngsee J, Lavoie MJ, Slack RS, Rao Y, Zhang Z, Lu B, Haque ME, Park DS. Human molecular genetics. 2009 18:4390-404.
LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. Yao C, El Khoury R, Wang W, Byrd TA, Pehek EA, Thacker C, Zhu X, Smith MA, Wilson-Delfosse AL, Chen SG. Neurobiology of disease. 2010 40:73-81. (ICC, IHC, WB)
Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. Hakimi M, Selvanantham T, Swinton E, Padmore RF, Tong Y, Kabbach G, Venderova K, Girardin SE, Bulman DE, Scherzer CR, LaVoie MJ, Gris D, Park DS, Angel JB, Shen J, Philpott DJ, Schlossmacher MG. Journal of neural transmission (Vienna, Austria : 1996). 2011 118:795-808. (WB; Mouse, Human)
LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study. Sharma S, Bandopadhyay R, Lashley T, Renton AE, Kingsbury AE, Kumaran R, Kallis C, Vilario-Gell C, O'Sullivan SS, Lees AJ, Revesz T, Wood NW, Holton JL. Neuropathology and applied neurobiology. 2011 37:777-90.
The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Liu Z, Lee J, Krummey S, Lu W, Cai H, Lenardo MJ. Nature immunology. 2011 12:1063-70.
Re-examination of the dimerization state of leucine-rich repeat kinase 2: predominance of the monomeric form. Ito G, Iwatsubo T. The Biochemical journal. 2012 441:987-94.
Sequences located within the N-terminus of the PD-linked LRRK2 lead to increased aggregation and attenuation of 6-hydroxydopamine-induced cell death. Pandey N, Fahey MT, Jong YJ, O'Malley KL. PloS one. 2012 7:e45149. (WB; Human)
LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein. Marker DF, Puccini JM, Mockus TE, Barbieri J, Lu SM, Gelbard HA. Journal of neuroinflammation. 2012 9:261. (ICC; Mouse)